Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Juni 2026 11:57 ET | Quelle: Human Continuum Inc.

Human Continuum Closes Over $5 Million in Seed Round Funding to Support the Development of its Integrated Exosome-Based Therapeutic Longevity Platform

Jupiter, F.L., June 11, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
07. Mai 2026 11:40 ET | Quelle: SNS Insider pvt ltd

Global Exosome-Based Therapy Market Size to Hit USD 288.10 Million by 2035 – SNS Insider

Austin, United States, May 07, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Exosome-Based Therapy Market was valued at USD 54.08 million in 2025 and is expected to reach USD 288.10 million...
24. Februar 2026 09:00 ET | Quelle: Human Continuum Inc.

Human Continuum Appoints Dr. Michael Milligan, MD, MBA, as its Chief Medical Officer to Oversee Innovative Applications for Next-Generation Extracellular Vesicle Therapeutics

New York, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
22. Januar 2026 09:00 ET | Quelle: Human Continuum Inc.

Human Continuum Appoints Dr. Omar Khalid Sial, Ph.D., as its Chief Scientific Officer to Spearhead the Development of Innovative Extracellular Vesicle Topical Formulations and Advanced Biologic Therapies

New York, N.Y., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...